Arjo AB (publ) develops and sells medical devices and solutions for patients with reduced mobility and age-related health challenges in North America, Western Europe, and internationally. More Details
Solid track record with moderate growth potential.
Share Price & News
How has Arjo's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ARRJ.F has not had significant price volatility in the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: Insufficient data to determine how ARRJ.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how ARRJ.F performed against the US Market.
Price Volatility Vs. Market
How volatile is Arjo's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Arjo undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ARRJ.F ($5.68) is trading above our estimate of fair value ($4.42)
Significantly Below Fair Value: ARRJ.F is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ARRJ.F is good value based on its PE Ratio (34x) compared to the US Medical Equipment industry average (48.8x).
PE vs Market: ARRJ.F is poor value based on its PE Ratio (34x) compared to the US market (17.4x).
Price to Earnings Growth Ratio
PEG Ratio: ARRJ.F is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: ARRJ.F is good value based on its PB Ratio (2.5x) compared to the US Medical Equipment industry average (3.7x).
How is Arjo forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARRJ.F's forecast earnings growth (23.7% per year) is above the savings rate (2.2%).
Earnings vs Market: ARRJ.F's earnings (23.7% per year) are forecast to grow faster than the US market (23% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ARRJ.F's revenue (4.6% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: ARRJ.F's revenue (4.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ARRJ.F's Return on Equity is forecast to be low in 3 years time (11.4%).
How has Arjo performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ARRJ.F has high quality earnings.
Growing Profit Margin: ARRJ.F's current net profit margins (4.6%) are higher than last year (4.1%).
Past Earnings Growth Analysis
Earnings Trend: ARRJ.F's earnings have grown by 11% per year over the past 5 years.
Accelerating Growth: ARRJ.F's earnings growth over the past year (19.5%) exceeds its 5-year average (11% per year).
Earnings vs Industry: ARRJ.F earnings growth over the past year (19.5%) exceeded the Medical Equipment industry 1.8%.
Return on Equity
High ROE: ARRJ.F's Return on Equity (7.4%) is considered low.
How is Arjo's financial position?
Financial Position Analysis
Short Term Liabilities: ARRJ.F's short term assets (SEK4.7B) exceed its short term liabilities (SEK3.9B).
Long Term Liabilities: ARRJ.F's short term assets (SEK4.7B) do not cover its long term liabilities (SEK5.1B).
Debt to Equity History and Analysis
Debt Level: ARRJ.F's debt to equity ratio (99.7%) is considered high.
Reducing Debt: ARRJ.F's debt to equity ratio has increased from 17.7% to 99.7% over the past 5 years.
Debt Coverage: ARRJ.F's debt is well covered by operating cash flow (30.2%).
Interest Coverage: ARRJ.F's interest payments on its debt are well covered by EBIT (5.4x coverage).
What is Arjo current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ARRJ.F's dividend (1.23%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.75%).
High Dividend: ARRJ.F's dividend (1.23%) is low compared to the top 25% of dividend payers in the US market (5.03%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, ARRJ.F has been paying a dividend for less than 10 years.
Growing Dividend: ARRJ.F's dividend payments have increased, but the company has only paid a dividend for 2 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (41.9%), ARRJ.F's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: ARRJ.F's dividends in 3 years are forecast to be well covered by earnings (32.6% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Joacim Lindoff (47 yo)
Mr. Joacim Lindoff, M.Sc. (Economics), has been the Chief Executive Officer and President at Arjo AB (publ). since 2017. He was President of Patient & Post-Acute Care at Getinge AB and wasa aslo its Acti ...
CEO Compensation Analysis
Compensation vs Market: Joacim's total compensation ($USD1.19M) is below average for companies of similar size in the US market ($USD4.65M).
Compensation vs Earnings: Joacim's compensation has been consistent with company performance over the past year.
|CEO, President & Director||3.67yrs||kr10.89m||0.0061% |
|Chief Financial Officer||0.50yr||no data||0.0037% |
|Executive Vice President of Product Development||3.67yrs||no data||0.021% |
|Vice President of Investor Relations & Corporate Communications||0.42yr||no data||no data|
|Executive VP of Legal & Business Compliance and Board Secretary||0.67yr||no data||no data|
|Executive Vice President of Marketing Communication & Public Relations||no data||no data||0.0016% |
|President Global Sales & Service||no data||no data||no data|
|Executive Vice President of Human Resources & CSR||3.67yrs||no data||no data|
|Executive Vice President of Quality & Regulatory Compliance||3.67yrs||no data||no data|
|Executive VP & Chief Strategy Officer||3.67yrs||no data||no data|
|President of Sales & Service North America||3.67yrs||no data||no data|
Experienced Management: ARRJ.F's management team is considered experienced (3.7 years average tenure).
|CEO, President & Director||3.67yrs||kr10.89m||0.0061% |
|Vice Chairman||2.67yrs||kr684.00k||no data|
|Chairman of the Board||3.67yrs||kr1.51m||0.037% |
|Independent Director||3.08yrs||kr713.00k||0.0073% |
|Independent Director||3.67yrs||kr713.00k||0.0011% |
|Employee Representative Director||3.67yrs||no data||no data|
|Employee Representative Director||3.67yrs||no data||0.0015% |
|Deputy Board Member||3.67yrs||no data||no data|
|Deputy Board Member||2yrs||no data||no data|
Experienced Board: ARRJ.F's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Arjo AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Arjo AB (publ)
- Ticker: ARRJ.F
- Exchange: OTCPK
- Founded: 1957
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr14.844b
- Listing Market Cap: kr1.625b
- Shares outstanding: 272.37m
- Website: https://www.arjo.com
Number of Employees
- Arjo AB (publ)
- Hans Michelsensgatan 10
- Skåne County
- 211 20
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ARJO B||OM (OMX Nordic Exchange Stockholm)||Yes||Class B Shares||SE||SEK||Dec 2017|
|ARJOBS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Class B Shares||GB||SEK||Dec 2017|
|0HQ8||LSE (London Stock Exchange)||Yes||Class B Shares||GB||SEK||Dec 2017|
|ARRJ.F||OTCPK (Pink Sheets LLC)||Yes||Class B Shares||US||USD||Dec 2017|
|A39||DB (Deutsche Boerse AG)||Yes||Class B Shares||DE||EUR||Dec 2017|
Arjo AB (publ) develops and sells medical devices and solutions for patients with reduced mobility and age-related health challenges in North America, Western Europe, and internationally. The company offer ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/26 05:42|
|End of Day Share Price||2020/09/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.